Efficacy and Safety of Intradermal RN1001 (Avotermin) in Elderly Subjects.
A Trial to Investigate the Accelerated Wound Healing and Antiscarring Potential, Safety, Toleration and Systemic Exposure of Intradermal RN1001 (Avotermin) in Male and Female Subjects Aged 60 Years and Over.
Sponsor: Renovo
A PHASE1/PHASE2 clinical study on Cicatrix, this trial is completed. The trial is conducted by Renovo and has accumulated 4 data snapshots since 2002. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
4 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Jan 2017 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
First recorded
Sep 2002
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Renovo
For direct contact, visit the study record on ClinicalTrials.gov .